Hypertrophic cardiomyopathy (HCM) is a heterogeneous inherited cardiac condition that affects 0.2% of the general population (1). It is typified by a hypertrophied nondilated left ventricle (LV) with resting or provocable LV outflow tract (OT) obstruction, observed in up to two-thirds of ...
To determine the sensitivity of the isolation method for SARS-CoV-2 from clinical samples, a virus stock titered by plaque assay (HCM/V/53), a passage 3 working bank grown from SARS-CoV-2 Strain England 2, from Public Health England, was diluted in minimum essential medium to give virus...
Methods In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II–III symptoms ...
(EXPLORER-HCM) in 68 clinical cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II-III symptoms were assigned (1:1) to receive mavacamten (starting at 5 mg) or placebo...